Quick Answer
Imunon, Inc. reported R&D Expense of $7.78 million for fiscal year 2025.
Imunon, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.78M | -33.2% |
| 2024 | $11.64M | +3.1% |
| 2023 | $11.29M | -3.8% |
| 2022 | $11.73M | +10.5% |
| 2021 | $10.62M | -6.4% |
| 2020 | $11.34M | -13.2% |
| 2019 | $13.07M | +10.1% |
| 2018 | $11.87M | -9.3% |
| 2017 | $13.08M | -10.6% |
| 2016 | $14.62M | -0.3% |
| 2015 | $14.66M | -2.1% |
| 2014 | $14.97M | +59.9% |
| 2013 | $9.36M | -40.6% |
| 2012 | $15.77M | -20.6% |
| 2011 | $19.86M | +35.0% |
| 2010 | $14.71M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.90M | -42.3% | +54.8% |
| June 30, 2025 | $1.23M | -56.5% | -43.3% |
| March 31, 2025 | $2.17M | -34.3% | -34.3% |
| September 30, 2024 | $3.29M | +66.3% | +16.8% |
| June 30, 2024 | $2.82M | -10.0% | -14.4% |
| March 31, 2024 | $3.29M | +25.7% | +66.3% |
| September 30, 2023 | $1.98M | -17.8% | -36.8% |
| June 30, 2023 | $3.13M | -2.8% | +19.6% |
- Imunon, Inc. showed a decrease of -33.2% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2025 period, Imunon, Inc.’s r&d expense has declined by 47.1% (from $14.71 million to $7.78 million).
- The most recent figure is from Imunon, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: